Next Article in Journal
Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk
Next Article in Special Issue
Preventive Effects of Heat-Killed Enterococcus faecalis Strain EC-12 on Mouse Intestinal Tumor Development
Previous Article in Journal
Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream
Previous Article in Special Issue
Preventive Effects of Pentoxifylline on the Development of Colonic Premalignant Lesions in Obese and Diabetic Mice
Review

The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy

1
Department of Medicine, St. Thomas Health Mid-Town Hospital, Nashville, TN 37236, USA
2
Department of Biological Sciences, Tennessee State University, 3500 John A Merritt Blvd, Nashville, TN 37209, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Takuji Tanaka and Masahito Shimizu
Int. J. Mol. Sci. 2017, 18(3), 650; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030650
Received: 9 January 2017 / Revised: 6 March 2017 / Accepted: 13 March 2017 / Published: 17 March 2017
(This article belongs to the Special Issue Inflammation and Cancer)
DNA-based vaccine strategy is increasingly realized as a viable cancer treatment approach. Strategies to enhance immunogenicity utilizing tumor associated antigens have been investigated in several pre-clinical and clinical studies. The promising outcomes of these studies have suggested that DNA-based vaccines induce potent T-cell effector responses and at the same time cause only minimal side-effects to cancer patients. However, the immune evasive tumor microenvironment is still an important hindrance to a long-term vaccine success. Several options are currently under various stages of study to overcome immune inhibitory effect in tumor microenvironment. Some of these approaches include, but are not limited to, identification of neoantigens, mutanome studies, designing fusion plasmids, vaccine adjuvant modifications, and co-treatment with immune-checkpoint inhibitors. In this review, we follow a Porter’s analysis analogy, otherwise commonly used in business models, to analyze various immune-forces that determine the potential success and sustainable positive outcomes following DNA vaccination using non-viral tumor associated antigens in treatment against cancer. View Full-Text
Keywords: DNA vaccine; T-cells; cytokines; immune checkpoint inhibitors; tumor associated antigens DNA vaccine; T-cells; cytokines; immune checkpoint inhibitors; tumor associated antigens
Show Figures

Graphical abstract

MDPI and ACS Style

Amara, S.; Tiriveedhi, V. The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int. J. Mol. Sci. 2017, 18, 650. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030650

AMA Style

Amara S, Tiriveedhi V. The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. International Journal of Molecular Sciences. 2017; 18(3):650. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030650

Chicago/Turabian Style

Amara, Suneetha, and Venkataswarup Tiriveedhi. 2017. "The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy" International Journal of Molecular Sciences 18, no. 3: 650. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030650

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop